Purification and characterization of a new β-lactamase OXA-205 from Pseudomonas aeruginosa

Abstract

BackgroundWe have identified a novel class 1 integron (1503 bp), named In671 in a clinical Pseudomonas aeruginosa isolate. Integron sequence analysis revealed two gene cassettes, one coding for a new OXA-type β-lactamase designated as OXA-205 and the other coding for the aadB gene that is responsible for aminoglycoside resistance. The 266 amino acid sequence of OXA-205 revealed that this β-lactamase belongs to the Ambler class D showing highest sequence homology to the OXA-2 sub-lineage. Our objective was to purify and characterize β-lactamase OXA-205.MethodsEscherichia coli cells were transformed with a plasmid containing cloned blaOXA-205 gene from P. aeruginosa. Purification of overproduced OXA-205 consisted of a single ion-exchange chromatography step. SDS-PAGE and isoelectric focusing were performed to determine the molecular mass and pI, respectively. Size-exclusion chromatography was undertaken to determine the OXA-205 oligomerization state. Substrate hydrolysis reactions were employed to assess enzyme kinetic parameters.ResultsPurification of OXA-205 yielded the enzyme with >95 % purity (as verified by SDS-PAGE). Approximate yield of the protein was estimated to be 20 mg per liter of culture. OXA-205 had a pI at 8.1, molecular mass of 26 kDa and a monomeric native structure. Kinetic analysis revealed that OXA-205 hydrolyzed narrow spectrum substrates, including ampicillin, carbenicillin, oxacillin, penicillin G, cefazolin and cefuroxime. Additionally, we observed a substrate inhibition profile towards carbenicillin and oxacillin, but not with ampicillin or penicillin G. Our results also show that OXA-205 conferred unusually high (among class D β-lactamases) resistance towards inhibition by NaCl.ConclusionsOXA-205 can be considered a narrow spectrum monomeric β-lactamase that demonstrates unusually high resistance profile towards inhibition by NaCl.Electronic supplementary materialThe online version of this article (doi:10.1186/s12941-015-0113-1) contains supplementary material, which is available to authorized users.

<p>In Vitro Activity Of Ceftaroline And Comparators Against <em>Staphylococcus aureus</em> Isolates: Results From 6 Years Of The ATLAS Program (2012 To 2017)</p>

“…During the study period and across the five geographical regions covered by ATLAS, MRSA represented 58.7% of S. aureus isolates. This rate is higher than that of the Tigecycline Evaluation and Surveillance Trial (TEST) (40.2%)18 and TEST study specific to blood-borne infections (33.0%) 19. The SENTRY surveillance report for Asia-Pacific and Latin America showed MRSA rates of 37.0% and 44.7%, respectively,20,21 which are lower than in the ATLAS study.…”

“…Previous studies reported that the lowest antibiotic susceptibility of blood-borne infections from S. aureus was to penicillin (around 15%) 18,19. A surveillance study from the Antimicrobial Resistance Surveillance Network in Germany reported that the susceptibility of MRSA to linezolid, teicoplanin, tigecycline, and vancomycin was high 22.…”

<p>Comparative genomic analysis and multi-drug resistance differences of <em>Acinetobacter baumannii</em> in Chongqing, China</p>

“…The disinfectant resistance gene QacE confers resistance to quaternary ammonium salt disinfectants 40. A mutation in this gene was found in each of the ten A. baumannii isolates.…”

<p>Characterization of a carbapenem- and colistin-resistant<em> Enterobacter cloacae</em> carrying Tn<em>6901</em> in <em>bla</em>_NDM-1 genomic context</p>

“…Carbapenem-resistant E. cloacae has been commonly reported in Vietnam and many other countries in the world 14–16. However, colistin resistance in E. cloacae has not been reported widely, particularly carbapenemase-producing colistin-resistant E. cloacae has very recently been reported from some countries including India,10 the United States,17 and China 18–20…”